The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Not understand Wyndrum. Ofcourse I could be wrong as not technical, but don't understand why TT will be required (for the swab) because BBI are developing it & then presumeably will manufacture. The saliva test is a different matter, although if BBI were to re-design I would ask the same question.
However, if there are to be multiple producers (for both lfd) TT to them will be necessary, I guess.
"I am delighted with the excellent progress that has been made with BBI Solutions in developing a scalable version of a lateral flow rapid SARS-CoV-2 antigen test"
What TT has to occur? BBI are developing the offering.
https://avacta.com/sars-cov-2-rapid-antigen-test-update/
Can someone offer enlightenment as I'm ignorant of the significance of this.
The diagnostic business unit has also made good progress on a number of other non-COVID-19 commercial opportunities and on putting in place an ISO13485 accredited quality system to support the future growth.
Picked out by an unmentionable ex contributor.
"It has been invited by NHS Test and Trace and the University of Oxford to participate in urgent research into the effectiveness of a new screening test. "
Urgent research... testing effectiveness of new screening test. Unless Innova rolling out an updated version it's unlikely to be theirs.
Thanks Dave.
Don't see ANY trades today. Can someone confirm whether this so. If correct, either a technical blip, or............?
Moniman's correct, Avacta is seen by many as a one trick pony.
Obviously all those who feel that way have done absolutely no research AND they didn't read the rns which also referred to ava6000.
Perdita Barran states "So, back to @OfficialUoM
.. our pilot a rapid response, and for MassSpec, we are using a method that deactivates the virus after swab, which was not in the supply chain. "
Can anyone confirm that our test uses a method that deactivates the virus after swab?
From the Sharebuyers interview published 27 October "This is clearly a value driver of a scale that may only happen once in a lifetime and Avacta is working with world-class lateral flow test developers and manufacturers to harness the Affimer reagents that work so well in the ELISA test to create a rapid saliva-based coronavirus test as soon as possible."
Unless we have the pregnancy style saliva test developed by Cytiva there can be no tech to transfer! And, too many consequential imponderables.
If ours, it could be they need to test against the various different manufacturers ms machines currently in situ. It is supposed to be of use across all/most platforms. Consequence, 20k tests insufficient.
Also, we're not the only new (ms) tech on the block that has something of interest that needs to go through the test mill.
@whimax Unfortunately, the journey of the sp does not make sense (to me). It certainly was overvalued at £3, but even without Accustem current sp looks very oversold. I feel the ADR & Accustem events were handled poorly. I think by & large Tils is way, way under the radar, being only appreciated by the handful of very substantial investors (there until the end game) & larger group of much smaller investors (far more volatile). The (relatively) small amount of shares in public hands offers a leveraged opportunity for manipulation (by whom?) which I think we are seeing. Very much a case of the 'tail wagging the dog'.
Could easily be completely wrong. Hopefully we'll see this unsettling trend/sentiment reversed with conviction by the year.
Seems to be in complete control on Nasdaq. The shorting interest yesterday was an extraordinary 39%. While remaining mid/long term optimistic I would certainly hesitate to invest any/further funds until something really positive emerges.
@Poundcake - from rns 22July
Adeptrix's novel BAMS platform uses Affimer reagents to capture the virus and viral proteins from patient samples and combines this with the power of mass-spectrometry analysis to provide a highly sensitive and specific diagnostic test. Up to 1,000 nasopharyngeal swab or saliva samples per day can be analysed by a single technician using the BAMS assay, making it a very attractive high throughput technique for COVID-19 screening in the clinical setting.
@busymum. Think your post @ 8:49 a tad risque for the morning. Ok for post evening watershed.
The above coy is listed as a new holder of some 192k+ shares as at 30 Sept.
According to WikiP " It is one of the largest asset management companies in the world with US$2.511 trillion under management and US$31.62 trillion under custody and administration. It is the second largest custodian bank in the world."
Be surprised if they have invested on a whim.